Member of the Legislative Council Natasha Maclaren-Jones today  welcomed the NSW Government’s announcement that a Memorandum of Understanding (MOU) has been signed with GW Pharmaceuticals (GW) to progress a major new research program for cannabis-based medicines in children with severe, drug resistant paediatric epilepsy.

Mrs Maclaren-Jones said many children are suffering and this announcement provides hope for families.

“This is a Government showing incredible progress, NSW is the first state in Australia to provide legal and safe access to cannabis-based medicines for children suffering from drug resistant epilepsy,” Mrs Maclaren-Jones said.

The MOU will facilitate:

  • A world first, phase 2 clinical trial in children for GW’s novel product containing the cannabinoid cannibidivarin (CBDV)
  • A compassionate access scheme for EpidiolexÒ, GW’s product containing cannabidiol (CBD) which is currently in late stage trials in paediatric epilepsy in the United States
  • Provision for NSW to host additional Phase 3 clinical trials of EpidiolexÒ in children with treatment-resistant epilepsy
  • A phase 4 clinical trial of EpidiolexÒ based on phase 3 studies

 

The MOU, between the NSW Government and GW Pharmaceuticals, comes as part of the NSW Government’s $21 million commitment to support clinical trials and establish the NSW Centre for Medicinal Cannabis Research and Innovation.

More information about medicinal cannabis in NSW is available at www.health.nsw.gov.au/cannabis.

Specific information regarding trials email cannabistrials@doh.health.nsw.gov.au or call the Cannabis Trials Help Line on 1800 217 257.